Next Science Study Shows Promise in Eliminating Surgical Site Infections

Next Science Ltd (ASX: NXS) has released preliminary study results showing the effectiveness of its XPERIENCE product in eliminating surgical site infection.

These studies were conducted by Dr Ravi K. Bashyal, an orthopaedic surgeon based in Chicago, Illinois.

Initial results are promising. They show XPERIENCE to be efficacious in preventing joint infection in patients undergoing knee and hip replacements.

This positive news led to a rise in the company’s share price, which last traded 9% higher intra-day at A$0.42.

2022 study

In a group of 471 patients undergoing knee or hip replacements in 2022, XPERIENCE achieved a zero per cent surgical site infection (SSI) rate.

This compares favourably to the control group (824 patients from 2020 and 2021) with a 0.5% infection rate (4 patients).

The paper outlining this study has been submitted and is expected to be published in the coming months.

Repeat study in 2023

To test the results over a broader period, the 2022 study was repeated in 2023 with 1,000 patients.

As of mid-March 2024, with the final patients nearing their 90-day follow-up, the SSI rate remains at zero per cent.

Data collection for this study was scheduled for completion at the end of March 2024 with publication expected later in the year.

XBIO suite

Next Science is a medical technology company focused on commercialising its proprietary XBIO suite of products to reduce the impact of biofilm-based infections in humans.

The company had cash of A$9.2 million on 31 December 2023.

Managing Director I.V. Hall said: “We are delighted that with the use of our XPERIENCE product, Dr Bashyal, a leading orthopaedic surgeon, has reduced to zero the rate of Surgical Site Infection amongst his patients up to 90 days post-surgery.”

 

 

Disclaimer

JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest